Recommendations on Eliminating Racial Disparities in Multiple Myeloma Therapies: A Step toward Achieving Equity in Healthcare
2021
African Americans are at higher risk of multiple myeloma (MM) yet are underrepresented in clinical trials and reap fewer benefits from novel therapies of the disease. To improve representation of African Americans in MM clinical trials, researchers, healthcare providers, patients, industry partners, and regulators at an FDA–AACR workshop developed recommendations to all stakeholders. The outlined principles offer a road map to addressing disparities broadly in clinical trials.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
11
References
7
Citations
NaN
KQI